Valuation dashboard for Bio-Techne Corporation (TECH) with P/E 62.41, P/B 5.23, EV/EBITDA 32.15 and dividend yield 0.45%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology.
Analysis Summary
Bio-Techne Corporation reported revenue of $1.22B in the most recent fiscal year, growing at a 5-year CAGR of 5.5%. Net income reached $181.9M, with a 5.3% 5-year CAGR.
Trailing-twelve-month margins: gross margin 65.8%, operating margin 20.7%, net margin 15.0%.
At the current price of $72.58, TECH trades at a P/E of 62.41 and an ROE of 8.63%. Market capitalisation stands at $11.4B, placing it among large-cap names.
Balance sheet quality for TECH: current ratio of 4.5. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| P/E Ratio | 62.41 |
| Price / Book | 5.23 |
| EV / EBITDA | 32.15 |
| Dividend Yield | 0.45% |
Valuation Models
| DCF Fair Value | $21.66 |
| vs Current Price | -70.2% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| TECH | Bio-Techne Corporation | $11.3B | 62.41 | 5.23 | 8.6% |
| MRNA | Moderna, Inc. | $75.4B | 11.13 | -39.2% | |
| JAZZ | Jazz Pharmaceuticals plc | $14.9B | 15.50 | 3.10 | -8.2% |
| MDGL | Madrigal Pharmaceuticals, Inc. | $11.8B | 27.79 | -56.6% | |
| EXEL | Exelixis, Inc. | $14.9B | 17.75 | 7.94 | 42.5% |
| BMRN | BioMarin Pharmaceutical Inc. | $11.1B | 150.47 | 1.75 | |
| CAI | Caris Life Sciences, Inc. | $8.6B | 76.10 | 13.53 | 18.8% |
| CORT | Corcept Therapeutics Incorporated | $12.6B | 223.52 | 17.35 | 8.4% |
Price
| Price | $72.58 |
| Market Cap | $11.4B |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | 8.63% |
| Return on Invested Capital | 7.52% |
| Return on Assets | 6.79% |
| Gross Margin | 65.77% |
| Operating Margin | 20.73% |
| Net Margin | 14.97% |
Related companies: BMRN · CAI · CORT · EXEL · JAZZ · MDGL · MRNA
Explore sector: Healthcare · Biotechnology
More sections of TECH: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks